6 Conclusions

6 Conclusions

6.1 The Committee concluded that the evidence demonstrated that the transurethral resection in saline (TURis) system was of equivalent efficacy to the monopolar system for transurethral resection of the prostate (TURP). It noted the important clinical advantages of TURis are reducing the risk of TUR syndrome that exists with monopolar TURP and reducing the need for blood transfusion. The Committee considered that it is plausible that TURis will also reduce length of hospital stay and reduce readmissions after surgery, although the evidence on these outcomes was limited.

6.2 The Committee accepted the External Assessment Centre revised model and sensitivity analyses and judged that, although uncertainty remained in the cost model, the use of the TURis system is likely to generate cost savings compared with the monopolar TURP system. It acknowledged that cost savings would be easier to achieve in hospitals that currently use Olympus monopolar systems. The Committee concluded that the case for adoption of the TURis system for transurethral resection of the prostate was supported by the evidence.

Andrew Dillon
Chief Executive
February 2015

  • National Institute for Health and Care Excellence (NICE)